{"id":"paritaprevir-ritonavir-ombitasvir-dasabuvir-ribavirin","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Pruritus"},{"rate":"10-15","effect":"Asthenia"},{"rate":"5-10","effect":"Elevated bilirubin"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage; ritonavir is a pharmacokinetic booster that increases paritaprevir levels; ombitasvir is an NS5A inhibitor that disrupts viral RNA replication; and dasabuvir is an NS5B polymerase inhibitor that blocks viral RNA synthesis. Together, these agents target distinct steps in the HCV replication cycle, achieving high cure rates across multiple HCV genotypes.","oneSentence":"This combination inhibits hepatitis C virus (HCV) replication by blocking multiple viral enzymes essential for viral protein processing and RNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:48.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotypes 1a and 1b, with or without cirrhosis"},{"name":"HCV genotype 1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT02460133","phase":"PHASE4","title":"Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2015-07-10","conditions":"Hepatitis C Virus","enrollment":44},{"nctId":"NCT02219490","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-30","conditions":"Chronic Hepatitis C Virus (HCV) Infection Genotype 1","enrollment":1596},{"nctId":"NCT02634008","phase":"PHASE3","title":"Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-06","conditions":"Hepatitis C, Acute","enrollment":83},{"nctId":"NCT02167945","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-06-12","conditions":"Chronic Hepatitis C Virus (HCV) Infection Genotype 1","enrollment":615},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":1275},{"nctId":"NCT02194998","phase":"PHASE2","title":"Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-09-16","conditions":"HIV Infections, Hepatitis C","enrollment":46},{"nctId":"NCT02486406","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-28","conditions":"Chronic Hepatitis C Infection","enrollment":64},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT01715415","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Chronic Hepatitis C Infection","enrollment":395},{"nctId":"NCT02582632","phase":"PHASE3","title":"A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-24","conditions":"Hepatitis C Infection, Hepatitis C Virus","enrollment":166},{"nctId":"NCT01939197","phase":"PHASE2, PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":318},{"nctId":"NCT02219503","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09","conditions":"Chronic Hepatitis C Infection, Compensated Cirrhosis","enrollment":60},{"nctId":"NCT01716585","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Chronic Hepatitis C Infection","enrollment":636},{"nctId":"NCT01674725","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-08","conditions":"Chronic Hepatitis C Infection","enrollment":187},{"nctId":"NCT01767116","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Chronic Hepatitis C Infection","enrollment":419},{"nctId":"NCT01995071","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":89},{"nctId":"NCT01704755","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-10","conditions":"Chronic Hepatitis C Infection, Compensated Cirrhosis","enrollment":381},{"nctId":"NCT01833533","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":305},{"nctId":"NCT02461745","phase":"PHASE4","title":"Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2015-06","conditions":"Hepatitis C, Chronic","enrollment":200},{"nctId":"NCT02609659","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-28","conditions":"Hepatitis C Virus (HCV)","enrollment":105},{"nctId":"NCT02803138","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-07","conditions":"Chronic Hepatitis C","enrollment":256},{"nctId":"NCT02615145","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-03","conditions":"Chronic Hepatitis C","enrollment":472},{"nctId":"NCT02851069","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-23","conditions":"Chronic Hepatitis C","enrollment":66},{"nctId":"NCT02734173","phase":"PHASE4","title":"Pilot HCV Direct Acting Antiviral Therapy and Metabolism","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2015-07","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT02636608","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-27","conditions":"Chronic Hepatitis C","enrollment":244},{"nctId":"NCT02618928","phase":"","title":"The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-15","conditions":"Chronic Hepatitis C","enrollment":735},{"nctId":"NCT02498015","phase":"PHASE4","title":"A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-08","conditions":"Hepatitis C, Chronic","enrollment":87},{"nctId":"NCT02582658","phase":"","title":"Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-06","conditions":"Chronic Hepatitis C","enrollment":173},{"nctId":"NCT02817594","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-20","conditions":"Chronic Hepatitis C","enrollment":51},{"nctId":"NCT02581163","phase":"","title":"Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-07","conditions":"Chronic Hepatitis C, Genotype 1 or 4","enrollment":314},{"nctId":"NCT02582671","phase":"","title":"The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-05","conditions":"Chronic Hepatitis C","enrollment":101},{"nctId":"NCT02581189","phase":"","title":"Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-13","conditions":"Chronic Hepatitis C","enrollment":565},{"nctId":"NCT02725866","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-05","conditions":"Chronic Hepatitis C","enrollment":216},{"nctId":"NCT03053180","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Chronic Hepatitis C","enrollment":60},{"nctId":"NCT02807402","phase":"","title":"Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-14","conditions":"Chronic Hepatitis C","enrollment":522},{"nctId":"NCT03710252","phase":"PHASE4","title":"A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study","status":"COMPLETED","sponsor":"American Research Corporation","startDate":"2016-03","conditions":"Chronic Hepatitis C","enrollment":100},{"nctId":"NCT02640547","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-26","conditions":"Chronic Hepatitis C","enrollment":394},{"nctId":"NCT02517528","phase":"PHASE3","title":"ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-07-20","conditions":"Chronic Hepatitis C Virus (HCV)","enrollment":104},{"nctId":"NCT01563536","phase":"PHASE2","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-02","conditions":"Chronic Hepatitis C Infection","enrollment":12},{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":"Chronic Hepatitis C Infection","enrollment":148},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT01911845","phase":"PHASE2","title":"An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04","conditions":"Chronic Hepatitis C Infection, Chronic Hepatitis C","enrollment":38},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT02356562","phase":"PHASE2","title":"A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-02-03","conditions":"Chronic Hepatitis C Infection","enrollment":29},{"nctId":"NCT02504099","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-07","conditions":"Chronic Hepatitis C Infection","enrollment":3},{"nctId":"NCT02207088","phase":"PHASE3","title":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09-23","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":68},{"nctId":"NCT01782495","phase":"PHASE2","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-02-25","conditions":"Chronic Hepatitis C Infection","enrollment":129},{"nctId":"NCT02493855","phase":"PHASE2","title":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06","conditions":"Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a","enrollment":46},{"nctId":"NCT02442284","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-05-13","conditions":"Chronic Hepatitis C, Cirrhosis, Hepatitis C Virus","enrollment":99},{"nctId":"NCT02476617","phase":"PHASE3","title":"Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06","conditions":"Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a","enrollment":25},{"nctId":"NCT02442271","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-27","conditions":"Chronic Hepatitis C Infection","enrollment":222},{"nctId":"NCT02219477","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-11-24","conditions":"Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus","enrollment":36},{"nctId":"NCT02399345","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-03","conditions":"Chronic Hepatitis C Virus (HCV Infection Genotype 1)","enrollment":10},{"nctId":"NCT02950870","phase":"PHASE4","title":"Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.","status":"UNKNOWN","sponsor":"University of Modena and Reggio Emilia","startDate":"2016-12","conditions":"Chronic Hepatitis, C Virus","enrollment":75},{"nctId":"NCT02216422","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":36},{"nctId":"NCT02646111","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors (\"PI\") Failures","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2016-01","conditions":"Hepatitis C","enrollment":120},{"nctId":"NCT01464827","phase":"PHASE2","title":"ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10","conditions":"Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1","enrollment":580}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin","genericName":"paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin","companyName":"American Research Corporation","companyId":"american-research-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits hepatitis C virus (HCV) replication by blocking multiple viral enzymes essential for viral protein processing and RNA synthesis. Used for Chronic hepatitis C virus (HCV) infection, genotypes 1a and 1b, with or without cirrhosis, HCV genotype 1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}